Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug;12(4):2597-2604.
doi: 10.1002/ehf2.15262. Epub 2025 Jun 9.

Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community

Roberto Pecoits-Filho  1   2 , Michelle M Y Wong  3 , Monica Moorthy  4 , Debasish Banerjee  5 , Suman Behera  6 , Viviane Calice-Silva  7 , Mogamat-Yazied Chothia  8 , Gates B Colbert  9 , Martha Gulati  10 , Charles A Herzog  11 , Fadi Jouhra  12 , Edgar V Lerma  13 , Charu Malik  4 , Kershaw V Patel  14 , Amina Rakisheva  15 , Giuseppe M C Rosano  16 , Priyanka Satish  14 , Henry H L Wu  17 , Angela Yee-Moon Wang  18
Affiliations
Editorial

Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community

Roberto Pecoits-Filho et al. ESC Heart Fail. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RPF reports non‐financial support from Fresenius Medical Care, Bayer, Astra Zeneca, Novo Nordisk, Fibrigen, Akebia, Boehringer, personal fees from Geroge Clinical, outside the submitted work; and RPF is employed by Arbor Research Collaborative for Health, who runs the DOPPS studies. Global support for the ongoing DOPPS Programs is provided without restriction on publications by a variety of funders. Funding is provided to Arbor Research Collaborative for Health and not to RPF directly. https://www.dopps.org/AboutUs/Support.aspx.

MMYW reports personal fees from George Clinical (consultant), personal fees from Astra Zeneca (Advisory Board on CKD early identification and intervention in Primary Care), and grants from Michael Smith Health Research BC (Research salary support), outside the submitted work.

MM reports personal fees from The International Society of Nephrology (consultant) outside the submitted work.

DB reports grants from AstraZeneca, BHF, and KRUK[JD1], and personal fees from AstraZeneca, Bayer, and Vifor Pharma, outside the submitted work.

GBC reports personal fees from AstraZeneca and Bayer, outside the submitted work.

CAH reports equity (stock) of Boston Scientific, Johnson &Johnson, Merck, and Pfizer, grants from Relypsa/Vifor and Bristol‐Meyers Squibb, and personal fees from AstraZeneca, Bayer, Diamedica, Fibrogen, Merck, NxStage, and Relypsa/Vifor, outside the submitted work.

EVL reports personal fees from Akebia/Otsuka, Astra Zeneca, Bayer, GSK, Otsuka, Travere, Vertex, Vifor, Elsevier, McGraw‐Hill, Springer, and Wolters Kluwer, outside the submitted work.

CM reports personal fees from The International Society of Nephrology (employee), outside the submitted work.

AYW reports speaker fees from Astra Zeneca, Bayer AG and Fresenius Kabi, reports travel fees from Astra Zeneca, Bayer AG and Fresenius Kabi, served as advisory board member of Fresenius Kabi and served as Executive Committee member of CSL Behring sponsored trial. All other authors have nothing to disclose. [Correction added on 06 June 2025, after first online publication: Angela Yee‐Moon Wang's disclosures have been added in this version.]

Figures

Figure 1
Figure 1
Optimization of RAASi Therapy Toolkit. ACEs = angiotensin‐converting enzyme inhibitor/s, ARBs = angiotensin receptor blocker/s, ARNis = angiotensin receptor‐neprilysin inhibitor/s, CKD = chronic kidney disease, MRA = non‐steroidal mineralocorticoid receptor antagonist/s, RAASi = renin–angiotensin–aldosterone system inhibitor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group . KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99:S1–S87. doi: 10.1016/j.kint.2020.11.003 - DOI - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group . KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022;102:S1–S127. doi: 10.1016/j.kint.2022.06.008 - DOI - PubMed
    1. Heidenreich PA, Bozkurt B, Aguillar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–e1032. doi: 10.1161/CIR.0000000000001063 - DOI - PubMed
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368 Erratum in: Eur Heart J. 2021 Oct 14 - DOI - PubMed
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269–1324. doi: 10.1161/HYP.0000000000000066 Erratum in: Hypertension. 2018;71(6):e136‐e139. Erratum in: Hypertension 2018;72(3):e33 - DOI - PubMed

Publication types

Grants and funding

LinkOut - more resources